

Information Update 21 January 2012

Progress Update Regarding the Invention Of Our Manufacturing System

I am pleased to announce that the second of the two key sub-systems of the overall manufacturing system which we are inventing and building is under production by a leading specialist manufacturer and shipment of the equipment to our U.S.A. general manufacturer is scheduled for 13 February 2012.

Upon delivery, this manufacturing sub-system will be integrated with the infrastructure of our manufacturing system, significantly increasing its as-built state. The other of the said two key sub-systems was incorporated into the manufacturing system in late December. Both said key equipment sub-systems involved the two most significant technological and engineering challenges we had to overcome in the invention process. Before the end of January, the production of yet another important equipment sub-system will be completed and it will be delivered to our general manufacturer and then mounted in place. When these two equipment and machinery systems are both mounted onto, and integrated with, the manufacturing system infrastructure, the invention of our manufacturing system will be at an advanced state of physical building completion. I project that if delivery of these two systems by the respective sub-manufacturers are on schedule, that the remaining work in building the manufacturing system will not involve any further ground-breaking technology or engineering and that from that point to full completion, the components which remain to be machined and mounted to the system will involve commonly used manufacturing parts, processes and techniques. I am confident that our never-done-before manufacturing system invention will be complete sometime this spring.

Patents

I am pleased to announce that last week we received official notice from the Japanese Patent Office that our prosecution of our Japanese patent application has been successful and that our syringe design patent application would be allowed, in full. Not one claim made in our application will be refused. The allowance of this particular application is a significant milestone for LOM for two reasons. Firstly, the Japanese Patent Office is a significant patent jurisdiction and it is known for its particularly rigorous patent examination process. A Patent grant from the Japanese Patent Office will be persuasive to other patent offices as they process our remaining patent applications. Secondly, the successful conversion of a patent application into a granted Patent will result in the creation of a valuable asset for LOM and will enable the commercialization of the technology. Japan will be a major potential market for our product and a granted Patent will give us exclusivity of access to that market. We are presently prosecuting our other patent applications, or waiting for the examination process to start, in numerous other countries. It is a highly complicated and technical process but we have succeeded with each application so far.

The provisional patent application filed over a new medical device co-invented by the President and a third party, will be followed by a regular patent application over the next few months.

Lionel Matthews, President, CEO